Get the Stockscreener App
1.125
5.14%
0.055
Clearside Biomedical Inc stock is traded at $1.125, with a volume of 281.49K.
It is up +5.14% in the last 24 hours and up +14.21% over the past month.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
See More
Previous Close:
$1.07
Open:
$1.1
24h Volume:
281.49K
Relative Volume:
1.12
Market Cap:
$81.15M
Revenue:
$8.23M
Net Income/Loss:
$-32.49M
P/E Ratio:
-2.1226
EPS:
-0.53
Net Cash Flow:
$-19.91M
1W Performance:
+20.97%
1M Performance:
+14.21%
6M Performance:
+9.22%
1Y Performance:
-18.48%
1-Day Range:
$1.06
$1.135
1-Week Range:
$0.9129
$1.135
52-Week Range:
$0.801
$2.12
Clearside Biomedical Inc Stock (CLSD) Company Profile
Name
Clearside Biomedical Inc
Sector
Industry
Phone
678-270-3631
Address
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Compare CLSD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
1.125 | 81.15M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.33 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.93 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.56 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.50 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-24 | Initiated | Chardan Capital Markets | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-21 | Resumed | Wedbush | Outperform |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| May-13-20 | Initiated | ROTH Capital | Buy |
| Aug-09-19 | Downgrade | Needham | Buy → Hold |
| Nov-05-18 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-05-18 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-05-18 | Downgrade | Stifel | Buy → Hold |
| Mar-06-18 | Reiterated | Needham | Buy |
| May-25-17 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-17 | Initiated | JP Morgan | Overweight |
| Nov-10-16 | Reiterated | Needham | Buy |
| Oct-24-16 | Reiterated | Stifel | Buy |
View All
Clearside Biomedical Inc Stock (CLSD) Latest News
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference - The Manila Times
Clearside Biomedical to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference - Nasdaq
Clearside Biomedical to Participate in Fireside Chat at the - GlobeNewswire
Inside Clearside Biomedical's Strategic Vision: CEO Fireside Chat at Major Healthcare Conference - StockTitan
Clearside Biomedical (NASDAQ:CLSD) Stock Passes Below 50-Day Moving AverageWhat's Next? - MarketBeat
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program - GlobeNewswire
Clearside Biomedical Announces Multiple Medical Meeting - GlobeNewswire
Revolutionary Eye Treatment Could Replace Monthly Injections for AMD Patients - StockTitan
Assenagon Asset Management S.A. Sells 125,190 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical (NASDAQ:CLSD) Stock Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Clearside Biomedical (CLSD) Stock Price, News & Analysis - MarketBeat
Clearside Biomedical Announces its Asia-Pacific Partner, - GlobeNewswire
Clearside's ARCATUS Eye Treatment Wins Historic First Approvals in Australia, Singapore - StockTitan
Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Significant Decline in Short Interest - MarketBeat
Geode Capital Management LLC Buys 59,089 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives $5.33 Average Price Target from Analysts - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of “Buy” by Analysts - Defense World
Clearside Biomedical (NASDAQ:CLSD) Stock Price Crosses Below 50-Day Moving Average – Here’s Why - Defense World
Clearside Biomedical (NASDAQ:CLSD) Shares Pass Below 50 Day Moving AverageWhat's Next? - MarketBeat
Further weakness as Clearside Biomedical (NASDAQ:CLSD) drops 14% this week, taking five-year losses to 72% - Simply Wall St
Clearside Biomedical stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa
Clearside Biomedical stock hits 52-week low at $0.92 - Investing.com
Clearside announces publication of insights on drug development, regulation - Yahoo Finance
Analyst Sees 500% Upside for This Pharmaceutical Penny Stock - GuruFocus.com
Clearside Biomedical Announces Publication of Critical - GlobeNewswire
Clearside Biomedical Unveils Groundbreaking Insights on Retinal Drug Development in Eye Journal - StockTitan
Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye - Yahoo Finance
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Brokerages Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $5.33 - MarketBeat
Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now - MSN
Clearside Biomedical's SWOT analysis: innovative eye treatment stock faces pivotal trial - Investing.com
Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Down 11.8% in November - MarketBeat
Clearside Biomedical (NASDAQ:CLSD) Upgraded to Hold at StockNews.com - MarketBeat
Clearside Biomedical's SWOT analysis: stock poised for potential breakthrough in wet AMD treatment - Investing.com Nigeria
Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Down 13.6% in November - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Large Decrease in Short Interest - MarketBeat
Clearside Biomedical (FRA:CLM) Momentum Rank : 5 (As of Nov. 30, 2024) - GuruFocus.com
Clearside showcases eye therapy delivery tech By Investing.com - Investing.com South Africa
Clearside showcases eye therapy delivery tech - Investing.com
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States - The Manila Times
Clearside Biomedical Extends Global Footprint with Numerous - GlobeNewswire
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Clearside Biomedical (FRA:CLM) Financial Strength : 4 (As of Sep. 2024) - GuruFocus.com
Clearside Biomedical Inc Stock (CLSD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clearside Biomedical Inc Stock (CLSD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chong Ngai Hang Victor | Chief Medical Officer |
Jun 24 '24 |
Buy |
1.06 |
23,500 |
24,910 |
63,500 |
| YERXA BENJAMIN R | Director |
May 15 '24 |
Buy |
1.31 |
7,813 |
10,235 |
17,957 |
| Gibney Anthony S | Director |
Apr 18 '24 |
Buy |
1.30 |
93,290 |
121,277 |
100,000 |
| Gibney Anthony S | Director |
Apr 17 '24 |
Buy |
1.25 |
6,710 |
8,388 |
6,710 |
| Chong Ngai Hang Victor | CHIEF MEDICAL OFFICER |
Mar 20 '24 |
Buy |
1.60 |
30,000 |
48,000 |
30,000 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):